Boundless Bio Inc. Common Stock

NASDAQ: BOLD
$10.66
+$0.65 (+6.5%)
Closing price April 23, 2024
Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.

Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter
A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as the second quarter began.
Trey Thoelcke
Published:

Top Analyst Upgrades and Downgrades: Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon, Sage Therapeutics, Target, Tesla, Trade Desk, Yext and More
Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade Desk and Yext.
Jon C. Ogg
Published:

Are Audentes Shareholders Getting Enough in the Acquisition?
Audentes Therapeutics shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just over three years, this...
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Alphabet, Amazon, Beyond Meat, CommScope, Enphase, Nabors, Netflix, Nike, Roku, Tesla, Uber, Williams Companies and More
Tuesday's top analyst upgrades, downgrades and initiations included Alphabet, Amazon.com, Beyond Meat, CommScope, Enphase Energy, Nabors Industries, Netflix, Nike, Roku, Tesla, Uber Technologies and...
Jon C. Ogg
Published:
Last Updated:

7 Biotechs With Catalysts in the Next Month
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.
Chris Lange
Published: